Jazz Pharmaceuticals plc

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-13 pm EST			5-day change	1st Jan Change
166.31 ^USD	+0.01%		+0.49%	-2.17%

Jan. 30	ALX Oncology Holdings Inc. Announces New Data from a Phase 1b/2 Clinical Trial Evaluating the Company's Investigational CD47-Inhibitor Evorpacept in Combination with Jazz Pharmaceuticals' ZIIHERTU	CI
Jan. 13	Jazz Pharmaceuticals plc Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 11:15 AM

Published on 01/09/2026 at 11:20 am EST - Modified on 01/09/2026 at 02:20 pm EST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning and welcome to the zanidatamab HERIZON-GEA-01 Investor Call and Webcast. [Operator Instructions] As a reminder, this conference call is

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Jan. 30	ALX Oncology Holdings Inc. Announces New Data from a Phase 1b/2 Clinical Trial Evaluating the Company's Investigational CD47-Inhibitor Evorpacept in Combination with Jazz Pharmaceuticals' ZIIHERTU	CI
Jan. 13	Jazz Pharmaceuticals plc Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 11:15 AM
Jan. 12	Truist Raises Price Target on Jazz Pharmaceuticals to $230 From $220, Keeps Buy Rating	MT
Jan. 08	Jazz Pharmaceuticals Names Chief Business Officer	MT
Jan. 08	RBC Trims Price Target on Jazz Pharmaceuticals to $191 From $194, Keeps Outperform Rating	MT
Jan. 06	Jazz Pharmaceuticals announce positive efficacy from Ziihera phase 3 trial	RE
Jan. 06	Zymeworks Inc. Announces Positive Efficacy and Safety Results from the Phase 3 HERIZON-GEA-01 Trial Evaluating Ziihera	CI
Dec. 10	This Is Decision Day
Dec. 10	Analyst recommendations: Abbvie, Biogen, PepsiCo, Eli Lilly, Netflix…
Dec. 09	Jazz Pharmaceuticals Insider Sold Shares Worth $797,783, According to a Recent SEC Filing	MT
Dec. 02	Jazz Pharmaceuticals plc Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 09:45 AM
Nov. 27	Saniona Reports Operating Profit of SEK 360 Million	FW
Nov. 24	Jazz Pharmaceuticals Insider Sold Shares Worth $607,127, According to a Recent SEC Filing	MT
Nov. 24	Jazz Gains From Ziihera Data, Upside Seen as Priced In, UBS Says	MT
Nov. 20	Jazz Pharmaceuticals Insider Sold Shares Worth $1,204,573, According to a Recent SEC Filing	MT